Antigenic determinants in type 1 diabetes mellitus. Review article

Nonobese diabetic mice express aspects of both type 1 and type 2 diabetes

Before the onset of autoimmune destruction, type 1 diabetic patients and an animal model, the nonobese diabetic (NOD) mouse, show morphological and functional abnormalities in target organs, which may act as inciting events for leukocyte infiltration. To better understand these abnormalities, but without the complications associated with lymphocytic infiltrates, we examined genes expressed in autoimmune target tissues of NOD/severe combined immunodeficient (scid) mice and of autoimmune-resistant C57BL/6/scid mice. Our results suggest that the NOD genetic background may predispose them to diabetic complications, including insulin resistance in the absence of high circulating glucose levels and without autoimmune destruction of their beta cells. Several of these genes lie within known type 1 and 2 diabetes loci. These data suggest that the NOD mouse may be a good candidate to study an interface between type 1 and type 2 diabetes.

The relationship between immune-mediated Type 1 diabetes mellitus and ethnicity

OBJECTIVE

To determine the proportion of adults with newly diagnosed Type 1 diabetes that had immune-mediated disease (IMD).

SUBJECTS AND METHODS

Two hundred fifteen patients with hyperglycemia and symptoms of insulin deficiency were screened for antibodies [islet cell antibodies (ICA), insulin autoantibodies (IAA), and glutamatic acid decarboxylase antibodies (GADA(65))] and HLA DR/DQ markers of IMD.

RESULTS

The mean age was 34 years and the mean BMI was 30.0 kg/m(2); 21.8% were non-Hispanic white (NHW), 27% were Latin American (LA), 47.9% were African American (AA), and 3.3% of other (OT) ethnic origins. Sixty individuals (28%) had one or more autoantibodies [Ab(+)]: 62% of NHW, 19% of AA, and 19% of LA. BMI was significantly lower (P<.01) in Ab(+). At least one HLA-DQ allele for susceptibility for IMD was identified in 52% of Ab(+).

CONCLUSIONS

These results suggest that islet cell autoantibodies and HLA markers of susceptibility for IMD are frequent in individuals of varying ethnic backgrounds, older age at onset, and higher body weight. Since early insulin therapy could delay what may otherwise be rapid progression to complete insulinopenia in patients with IMD, screening of adult diabetic patients for IMD at diagnosis may be of benefit to long-term management.

Current activities at the Centers for Disease Control and Prevention's National Diabetes Laboratory

In 1997, the Centers for Disease Control and Prevention established the National Diabetes Laboratory in order to help prevent and treat type 1 diabetes. This state-of-the-art laboratory collaborates with research scientists and key national and international organizations throughout the world to identify and study risk factors for type 1 diabetes by developing measurements for glycosylated proteins, developing and evaluating technology for measuring genetic risk factors for the disease, and working to standardize autoantibody measurements. Developing improved technologies for diagnosing and managing diabetes and developing reference materials for properly calibrating and standardizing blood glucose meters are also critical aspects of the laboratory's work. In addition, the laboratory provides quality storage for valuable collections of biologics and other materials and facilitates sharing of specimens, associated epidemiologic data, and test results. Working with our partners in diabetes research, we are improving the diagnosis, treatment, and prevention of type 1 diabetes.

Type 1 diabetes: the facts fit a deficient inhibitory signal given by MHC class II

This paper presents a hypothesis regarding the aetiology of Type 1 (autoimmune) diabetes, which suggests that autoimmunity is normally prevented by an inhibitory or negative signal delivered by MHC molecules, and that in Type 1 diabetes it is the inability of beta cells to deliver sufficient negative signal from MHC Class II that drives the underlying autoimmune process. Based on a broad survey of the diabetes literature, a list of clinical, pathological, experimental and epidemiological 'facts' about Type 1 diabetes is presented which are considered to be widely accepted as proven. The new theory is then compared to other recent theories on the aetiology of diabetes with regard to its ability to explain these accepted 'facts'.

Changes in protein kinase C in early cardiomyopathy and in gracilis muscle in the BB/Wor diabetic rat

Hyperglycemia can upregulate protein kinase C (PKC), which may be an important mediator of the progression from normal heart and muscle function to diabetic myopathy in the myocardium and skeletal muscle in type 1 insulin-dependent diabetes mellitus (IDM). We evaluated this possibility during the early stage of IDM in BB/Wor diabetic (D) rats and age-matched BB/Wor diabetes-resistant (DR) rats. Interventricular septal thickness, E wave peak velocity of tricuspid inflow (both minimum and maximum), and left ventricular (LV) weight index were increased, and the rate of change in LV pressure (LV dP/dt) decreased in D rats subjected to M-mode and two-dimensional echocardiography and hemodynamic recording of heart rate, LV pressure (LVP), + LV dP/dt, -LV dP/dt, and LV end-diastolic pressure (LVEDP) in vivo and in vitro 41 days after the onset of hyperglycemia. Whole ventricle basal PKC activity was increased by 44.4 and 18.4% in the particulate and soluble fractions, respectively, from D rats compared with that from DR rats using r-32P phosphorylation of appropriate peptide substrates. When measured by Western blot gel densitometry, particulate PKC-alpha and PKC-delta content increased by 89 and 24%, respectively, but soluble PKC-beta and soluble and particulate PKC-epsilon were unchanged compared with that of DR rats. Similarly, gracilis muscle PKC activity and PKC-alpha and PKC-delta were elevated in the gracilis muscle, whereas that of the circulating neutrophil did not differ between the D and DR rats. Thus, in vivo, the early diabetic cardiomyopathy of the D rat is characterized by a restrictive LV with increased septal thickness and is associated with elevated PKC activity and increased amounts of myocardial particulate PKC-alpha and PKC-delta, which are also seen in the skeletal muscle. We conclude that increased PKC isozymes may play a pivotal role during IDM in the development of diabetic cardiomyopathy and skeletal muscle myopathy.